Drug Pipeline

Azenosertib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
6
Active Studies
6
Recruiting
1
Phase 3
4
Top Sponsors
7
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC		 Trial terminated
2026-05-23 NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC		 critical why stopped: null → "Zentalis terminated contract due to concern for toxicity safety from previously reported serious adverse events."
2026-05-23 NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC		 Enrollment reduced: 78 -> 7 participants
2026-05-23 NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC		 date change Primary completion moved earlier: 2027-03-01 -> 2026-02-24
2026-05-23 NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC		 date change Completion moved earlier: 2029-09-01 -> 2026-02-24
2026-05-20 NCT07546500
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With…		 Recruitment opened
2026-05-20 NCT07546500
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With…		 Trial sites expanded: 0 -> 58 locations
Active Studies by Phase
Phase 3
1
Phase 2
2
Phase 1
2
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07546500 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With… Ovarian Cancer Recruiting
Phase 2
NCT06369155 Azenosertib in Uterine Serous Carcinoma: Biomarker Study Uterine Serous Carcinoma Recruiting
NCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous… High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting
Phase 1
NCT04516447 A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer Solid Tumor Recruiting
NCT06364410 Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and… Clinical Stage III Gastric Cancer AJCC v8 Recruiting
Early Phase 1
NCT04005690 Targeted Pathway Inhibition in Patients With Pancreatic Cancer Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting
Sponsors Running Azenosertib Trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (3) OHSU Knight Cancer Institute (1) National Cancer Institute (NCI) (1) Joyce Liu, MD (1)
Disease Areas
Ovarian Cancer (2) Pancreatic Cancer (1) Gastric Cancer (1) Endometrial Cancer (1)
Get alerts when Azenosertib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free